The CD146- CAFs inhibit the expression of estrogen receptor and response to estrogen, resulting in tamoxifen resistance, while the CD146+ CAFs provide durative estrogen-dependent proliferation and tamoxifen sensitivity of breast cancer cells (61). Here, ESR1 is linked to breast carcinoma.